My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 198

    1.

    Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.

    Cefalu WT, Schneider DJ, Carlson HE, Migdal P, Gan Lim L, Izon MP, Kapoor A, Bell-Farrow A, Terry JG, Sobel BE.

    Diabetes Care. 2002 Dec;25(12):2123-8.PMID: 12453948 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans.

    Edwards IJ, Terry JG, Bell-Farrow AD, Cefalu WT.

    Metabolism. 2002 Oct;51(10):1223-9.PMID: 12370838 [PubMed - indexed for MEDLINE]Related articles

    3.

    Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.

    Goldstein BJ, Pans M, Rubin CJ.

    Clin Ther. 2003 Mar;25(3):890-903.PMID: 12852706 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.

    Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, Chaiken R, Kourides I.

    Diabetes Res Clin Pract. 2005 May;68(2):167-75.PMID: 15860246 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes.

    Go EH, Kyriakidou-Himonas M, Berelowitz M.

    Diabetes Metab Res Rev. 2004 May-Jun;20(3):225-31.PMID: 15133754 [PubMed - indexed for MEDLINE]Related articles

    6.

    Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.

    Diabetes Care. 1997 Apr;20(4):597-606.PMID: 9096986 [PubMed - indexed for MEDLINE]Related articles

    7.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    8.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

    Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group.

    Diabetes Obes Metab. 2007 Mar;9(2):194-205.PMID: 17300595 [PubMed - indexed for MEDLINE]Related articles

    9.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    10.

    Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.

    Osei K, Rhinesmith S, Gaillard T, Schuster D.

    Metabolism. 2003 May;52(5):565-72.PMID: 12759885 [PubMed - indexed for MEDLINE]Related articles

    11.

    Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

    Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

    Pharmacotherapy. 2005 May;25(5):637-45.PMID: 15899724 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    13.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    14.

    Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

    Bays HE, Goldberg RB, Truitt KE, Jones MR.

    Arch Intern Med. 2008 Oct 13;168(18):1975-83.PMID: 18852398 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    16.

    The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.

    Chiasson JL, Naditch L; Miglitol Canadian University Investigator Group.

    Diabetes Care. 2001 Jun;24(6):989-94.PMID: 11375358 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

    Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

    18.

    Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

    Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

    Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

    Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708. PMID: 12832314 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity